trending Market Intelligence /marketintelligence/en/news-insights/trending/_ZhWc9FJYpQFDF01UZWvSQ2 content esgSubNav
In This List

Kitov Pharma to implement 1-for-20 reverse stock split

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Kitov Pharma to implement 1-for-20 reverse stock split

Kitov Pharma Ltd said its shareholders approved a 1-for-20 reverse stock split of the company's share capital.

The Israeli drug developer said the split will reduce its share capital to 250 million ordinary shares and 50 million preferred shares.

The move will also reduce the issued and outstanding ordinary shares of the company to about 16 million ordinary shares.

After the stock split, the ordinary shares will start trading on the Tel Aviv Stock Exchange on Jan. 6 and the American depositary shares on the Nasdaq on Jan. 7.